Product Description
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Molecular Templates
Company Location: AUSTIN TX 78729
Company CEO: Eric E. Poma
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Adenocarcinoma|Pancreatic Cancer|Sarcoma
Phase 2: Non-Small-Cell Lung Cancer|Sarcoma|Multiple Myeloma|Glioblastoma|Neuroendocrine Tumors|Biliary Tract Cancer|Melanoma|Astrocytoma|Glioma|Pancreatic Cancer|Adenocarcinoma|Prostate Cancer
Phase 1: Alopecia|Anorexia|Kidney Cancer|Liver Cancer|Neuroendocrine Carcinoma|Renal Cell Carcinoma|Thrombocytopenia|Neuroendocrine Tumors|Oncology Solid Tumor Unspecified|Hypertension|Anemia|Hypoxia|Neutropenia|Diarrhea|Acute Myeloid Leukemia|Hepatocellular Carcinoma|Islet Cell Adenoma|Islet Cell Carcinoma|Gastrointestinal Cancer|Pancreatic Cancer|Gastrointestinal Stromal Tumors|Esophageal Cancer|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Myelodysplastic Syndrome|Myelofibrosis|Acute Lymphoid Leukemia|Preleukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Head and Neck Cancer|Melanoma|Prostate Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUNINET | P2 |
Completed |
Neuroendocrine Tumors |
2020-01-10 |
|
| CTRC 12-0105 | P2 |
Completed |
Glioblastoma |
2019-01-04 |
|
| TH-CR-417 | P1 |
Unknown status |
Prostate Cancer|Pancreatic Cancer|Squamous Cell Carcinoma|Melanoma|Head and Neck Cancer |
2019-01-01 |
|
| GETNE-1408 | P2 |
Completed |
Pancreatic Cancer|Neuroendocrine Tumors |
2018-05-31 |